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Key points 23 
 This is the largest study of the  in-hospital management of epistaxis 24 
 Nasal cautery at the time of first specialist ENT review reduces treatment time by 25 
more than half, even after controlling for patient age, disease severity and whether 26 
patient was packed or not prior to ENT review.  27 
 Patients who receive a treatment algorithm that follows national guidance are 87% 28 
more likely to achieve haemostasis before patients who do not.  29 
 The 30-day hospital readmission rate is not affected by treatments that reduce 30 
treatment time.   31 
 32 
Abstract 33 
Importance: There is a paucity of high quality evidence relating to the management of 34 
epistaxis severe enough to require admission to a hospital. Previous studies of interventions 35 
for epistaxis have suffered from small sample sizes. They lacked the power to allow analysis 36 
of the effect of an intervention on epistaxis control that is independent of the condition 37 
severity or additional interventions given. 38 
 39 
Objective: To determine the effect of specialist treatments on the successful management 40 
of severe epistaxis 41 
 42 
Design: Secondary analysis of data collected from a national multi-centre audit of patients 43 
with epistaxis over 30 days in 2016. Data were entered prospectively, and patients were 44 
followed up for 30 days following hospital discharge.  45 
 46 
Setting: 113 participating UK hospitals.  47 
 48 
Participants: 1402 adults admitted for inpatient management of epistaxis were identified, 49 
with data entered prospectively during the 30-day audit window.  50 
 51 
Exposure: Exposure variables assessed included treatment instigated at first ENT review, 52 
intervention strategy during hospitalization, disease factors (e.g. severity), patient risk 53 
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factors (e.g. co-morbidities, medications) and treatment factors (grade of doctor, therapies 54 
initiated during hospital stay).   55 
 56 
Main Outcomes: Treatment time (time from first ENT review to time haemostasis was 57 
achieved and patient was safe for hospital discharge). 30-day hospital readmission rate.  58 
 59 
Results: 834 patients had sufficient data for inclusion. Patients who did not receive nasal 60 
cautery at first specialist review had a treatment time greater than double the time of those 61 
who were cauterised: Adjusted ratio (aR) 2.5 (95% CI 1.7-3.3), after controlling for age, 62 
bleeding severity, and whether they received a nasal pack or not.  Only 30% of patients 63 
received management that complied with new national guidance, but those that did were 64 
87% more likely to be achieve haemostasis before those that did not, even after controlling 65 
for bleeding severity. Type of treatment, whether initial intervention or management 66 
strategy, did not affect 30-day re-attendance.  67 
 68 
Conclusions and Relevance: Analysis of national audit data suggest that cautery at first 69 
specialist review, and management according to national guidance can reduce hospital 70 
treatment times without compromising 30-day re-attendance. Future work should 71 
investigate why early nasal cautery is infrequently used, and how service delivery can be 72 
optimised to allow widespread implementation of evidence-based management for 73 
epistaxis. 74 
 75 
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 83 
Introduction  84 
 85 
Epistaxis is common, with a lifelong incidence of 60% in the general population(1).  Most 86 
episodes of epistaxis are self-limiting, and only rarely is emergency medical treatment 87 
required when the bleeding becomes heavy or unrelenting (2). Despite this, there were 88 
nearly 25,000 in-hospital admissions to UK National Health Service hospitals (not including 89 
attendances to Emergency departments) in 2014-15 for epistaxis (3), accounting for more 90 
than £1.5 million in hospital bed costs alone, without factoring in the treatment costs (4).  91 
Emergency in-hospital interventions range from tamponade of the nasal cavity using nasal 92 
packs, cautery of bleeding vessels using chemicals or diathermy, or closing source arteries 93 
proximal to the bleeding point, using surgery or interventional radiology.  94 
 95 
A recent suite of systematic reviews was undertaken by INTEGRATE (the National ENT 96 
Trainee Research Collaborative) to summarise the published evidence regarding the 97 
management of epistaxis (5-8). There was limited evidence to suggest an association 98 
between epistaxis and age (9,10), sustained ambulatory hypertension (11) and 99 
cardiovascular disease (12). Identified studies suggested that nasal packing (13,14), nasal 100 
cautery (13,15,16), antithrombotic medications (17), surgery (18) and trans-catheter arterial 101 
embolization (19) all affected rates of epistaxis control. In-hospital management of epistaxis 102 
frequently involves patients of varying grades of disease severity, who receive more than 103 
one treatment. To date studies of epistaxis interventions have been typically of small 104 
sample size (20) , and often of insufficient power to calculate the effect of any individual 105 
intervention, independent of disease severity and additional treatments received (21).  106 
Previous audits of epistaxis management have shown considerable variation in practice that 107 
may reflect the uncertainty inherent in the current evidence (22,23).  108 
 109 
INTEGRATE, the UK ENT Trainee Research Network, recently undertook the largest 110 
prospective audit of adult inpatient epistaxis management to date, collecting data on more 111 
than 1200 cases across the United Kingdom over a 30-day observation window. Data 112 
captured included potential patient risk factors, interventions received during in-hospital 113 
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care, treatment success and 30-day re-admission data(24). Using this large and rich dataset, 114 
we aimed to investigate the role of different treatments and management strategies on 115 
successful in-hospital management of epistaxis. We analysed the role of initial interventions 116 
on overall treatment success, independent of subsequent treatments, patient factors and 117 
disease severity, and assessed the extent to which management strategies followed new 118 
guidelines (25), and the effect of this had on patient outcome.   119 
 120 
Methods  121 
Ethical approval 122 
NHS Research Ethics Committee guidance was sought regarding the use of the national 123 
audit dataset beyond a simple comparison against identified audit standards. Completion of 124 
the Health Research Authority Guidance Tool confirmed that formal NHS Research Ethics 125 
Committee approval was not required.  126 
 127 
Design 128 
Secondary analysis was performed on the dataset produced from a national audit of 129 
epistaxis management in adults (Cohort design). The pilot (22), final audit methods and 130 
preliminary results (24) have been described previously.  131 
 132 
Interventions analysed 133 
The impact of interventions was assessed in two ways. First, the type of initial intervention 134 
received by a patient (following assessment and supportive measures) was categorised as; 135 
cautery, intranasal packing, surgery, radiological embolisation or a combination of these. 136 
The effect of intervention type on outcome was assessed.  137 
 138 
Secondly, since the sequence of individual interventions undertaken during the whole 139 
admission would have been difficult to model and interpret, the effect of the overall 140 
management strategy during inpatient admission was investigated. Based on national 141 
consensus recommendations, endorsed by the British Rhinological Society (BRS) and ENT-142 
UK(25), we evaluated each patient’s management strategy (chronological order of 143 
interventions instigated during the hospital stay) to identify whether their management had 144 
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followed national recommendations (guidance compliant) or not (guidance non-compliant). 145 
Management strategies that were considered compliant with national guidelines are listed 146 
in the supplementary material. Two ENT surgeons (NM and RW), independently reviewed 147 
each patients’ management strategy to assess whether interventions had been undertaken 148 
in a chronological sequence that complied with national recommendations. Cases assessed 149 
differently by reviewers were discussed individually until consensus was reached. Where 150 
consensus could not be reached cases were referred to a senior surgeon (CH).  151 
 152 
Outcomes 153 
Two outcomes were selected:   154 
 155 
1. Treatment time (time from first ENT review to the point when haemostasis was 156 
achieved – i.e. the point at which the ENT team decided that the epistaxis had been 157 
resolved, and the patient was safe for hospital discharge). It excluded the time it 158 
took for the patient to be seen and treated in the Emergency Room, and the time it 159 
took for the patient to actually leave the hospital, which was occasionally delayed 160 
due to administrative or social issues.   161 
2. Hospital re-attendance rate with recurrent epistaxis within 30 days of discharge. This 162 
only included patients who re--attended under the ENT team for epistaxis. It did not 163 
include those who may have been successfully treated for recurrence through self-164 
care or their local primary and emergency care teams.  165 
 166 
These outcomes were chosen as they reflected both the early and longer-term efficacy of 167 
interventions, and they were readily extractable from the dataset available.  168 
 169 
Data Cleaning 170 
Data set cleaning was performed by statisticians (JC, BJ and KS), and any queries were dealt 171 
with by clinicians on the steering committee (NM, RW and MS). Data was included if the 172 
observation was within the audit period, was not a duplicate entry, and contained valid 173 
treatment times. A clinician scrutinised all participants with a treatment time of zero. If the 174 
This is an accepted authors draft of a paper published in Rhinology  
Received 09/10/2018, Accepted 26/11/2018,  
DOI: htttps://doi.org/10.4193/Rhin18.239 
 7 
clinician determined the treatment time of zero was invalid, treatment time was replaced 175 
with a suitable proxy; either discharge time or the last recorded time intervention. 176 
 177 
Statistical Analysis 178 
The statistical analysis was performed in three stages: i) identify which ENT initial individual 179 
interventions (intervention at first ENT review e.g. nasal cautery VERSUS nasal packing etc.) 180 
were associated with the treatment time for each case; ii) identify which intervention 181 
strategies (sequence of all interventions instigated throughout admission e.g. nasal packing 182 
then nasal cautery VERSUS nasal cautery then nasal packing, etc.) were associated with 183 
improved time to achieve haemostasis; and iii) identify which individual interventions and 184 
intervention strategies were associated with 30-day re-attendance to ENT. All statistical 185 
analyses were conducted in R statistical package (version 3.4.2)(26).  186 
 187 
Initial ENT (Individual) Interventions 188 
Exploratory analysis of the data was performed first to identify potential patient factors and 189 
individual interventions given at first ENT review that justified subsequent further 190 
inferential analysis via statistical models. In addition, a series of systematic reviews 191 
developed for the project (5-8) were also used to identify any additional potential 192 
associations. A full list of the patient factors investigated can be found in table 1. 193 
 194 
Treatment time by patient characteristics and individual interventions was summarised 195 
using the geometric mean and corresponding 95% confidence interval (CI). If the confidence 196 
intervals of mean treatment time overlapped within variable outcomes (e.g. mean 197 
treatment time for patients with hypertension overlapped with mean treatment time for 198 
patients without hypertension)then these variables were not tested for inclusion in the 199 
model, unless stated a priori.  200 
 201 
Approximately 60% of patients were successfully treated within 24 hours, and the remaining 202 
40% took between 1 and 7 days to achieve definitive management, resulting in a highly 203 
skewed distribution of treatment time. For this reason, analysis of initial individual 204 
interventions and treatment time was performed using linear regression on the log 205 
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transformed treatment time. It was decided a priori to adjust the models for age, bleed 206 
severity (via World Health Organization (WHO) bleeding severity grade) (27) and Modified 207 
Early Warning Score (MEWS)(28), regardless of their statistical significance. Forward model 208 
selection was used to identify the interventions and any additional patient characteristics 209 
associated with treatment time, and these were included in the model if a goodness-of-fit 210 
test yielded a p-value <0.05. We tested for interactions between different factors, but 211 
statistical evidence only supported the inclusion of one interaction, the initial intervention 212 
(packing or cauterisation) and whether further interventions were required.  213 
 214 
We performed sensitivity analysis (see supplementary material) to compare the differences 215 
between those who only required the initial interventions at their first ENT review with 216 
those who needed further interventions, by removing censored observations (i.e. removing 217 
those cases assigned proxy treatment times), and by WHO bleeding severity grade. 218 
 219 
Evidence from the exploratory analysis suggested that some categories of factors could be 220 
merged. The categories were combined once a clinician confirmed that the new categories 221 
remained clinically valid. Full details of the exploratory analysis have been previously 222 
published(24), including further detail, plots and summary statistics calculated from the 223 
Epistaxis audit.  224 
 225 
Due to the large number of factors to be investigated, we used forward model selection, 226 
and a factor was included in the model if there was evidence at the 5% significance level 227 
that the factor was contributing to the model. As more than 67% of patients required 228 
additional treatment after their first intervention, the log linear model for treatment time 229 
was adjusted for additional treatment performed after the first intervention, age, sex and 230 
markers of disease severity such as WHO bleeding severity grade (WHO grade 1 epistaxis 231 
<30 minutes within 24 hours, grade 2 epistaxis >30minutes within 24 hours, grade 3 232 
epistaxis severe enough to require blood transfusion)(27) and Modified Early Warning Score 233 
(MEWS is scored 0-3 based on systolic blood pressure, heart rate, respiratory rate, 234 
temperature and AVPU scales) (28). As there appeared to be two sub-populations of 235 
patients admitted with epistaxis – those successfully treated within 24 hours and those that 236 
required several ENT interventions - it was important to insure patient factors were 237 
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significantly related to treatment time across the entire population. Therefore, sensitivity 238 
analyses were performed to determine if the factor effect size remained consistent if 239 
patients with censored treatment time were excluded (e.g. Is WHO bleeding score related to 240 
treatment times in patients successfully treated within 24 hours as well as those that 241 
needed several interventions?) 242 
 243 
Intervention Strategy 244 
The sequence of interventions performed on each patient was used to determine whether 245 
the sequence followed the BRS epistaxis guidelines or not.  246 
 247 
Kaplan-Meier curves with 95% CI were used to explore the association between treatment 248 
time and the two distinct intervention strategies (guidance compliant and guidance non-249 
compliant), and patient factors. If CIs overlapped, further analysis was not performed as it 250 
was unlikely that there would be a statistically significant difference in the success of these 251 
different management strategies.  252 
 253 
To evaluate potential a relationship between intervention strategies and treatment time, a 254 
cox proportional hazard model was fitted to the data. It was decided to adjust the model for 255 
age, WHO bleeding severity grade and MEWS a priori. 256 
 257 
Re-attendance to ENT 258 
Factors potentially associated with re-attendance were identified via comparison of 259 
percentage 30-day re-attendance rate. If there was a difference >10% in re-attenance rate 260 
between groups characterised by the presence or absence of a certain factor, these factors 261 
were selected for further investigation. A difference of 10% was selected because the 95% 262 
CI for a percentage calculated from 100 observations is approximately ±10%, therefore 263 
differences less than this value were unlikely to be statistically significant.  264 
 265 
To identify factors associated with 30-day ENT re-attendance we fitted logistic regression 266 
models to the data. Forward selection was used to identify associated factors, and only 267 
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included if the goodness of fit p-value was <0.05. As with the previous models, it was 268 
decided a priori to adjust for age, WHO bleeding severity grade and MEWS.  269 
 270 
Results relating to the initial ENT (individual) intervention are presented as adjusted ratios 271 
(aR), which demonstrate the difference in treatment time between individual levels of a 272 
factor on a multiplicative scale, after adjusting for markers of disease severity (WHO grade 273 
and MEWS) and age. For example, if examining the role of initial ENT intervention X showed 274 
an aR of 2, it would mean that intervention X increased treatment time two-fold, even after 275 
controlling for disease severity and age, when compared to those who did not receive factor 276 
X. A censored time-to-event analysis was used to assess the association between guidance 277 
compliant intervention strategies and the treatment time.   278 
 279 
Results relating to intervention strategy are presented as adjusted hazard ratio (aHR), which 280 
demonstrate risk in relation to a timescale, on a multiplicative scale. For example, if 281 
examining the role of intervention strategy Z showed an aHR of 2, the result is best 282 
interpreted as patients receiving intervention strategy Z achieved haemostasis 66% faster 283 
than those that did not.   284 
 285 
Results 286 
The audit data set consisted of a total of 1826 entries recorded from 116 sites during the 287 
audit window. During data cleaning 305 entries were removed as duplicates, 89 were found 288 
to lie outside the audit period, and 30 patients were successfully treated prior to 289 
management by ENT. 280 patients had insufficient data to allow treatment times to be 290 
calculated (time of first ENT review or time of treatment completion) and 288 patients had 291 
incomplete data on key patient variables – described below- and were thus excluded from 292 
analyses of treatment time(n=834). 197 patients had insufficient data on ENT re-attendance 293 
and 417 had missing data on key patient variables – described below - and were thus 294 
excluded from analyses of re-attendance rate (n=788)(Figure 1 shows the number of 295 
patients who were included in the analysis). Patient data sets were incomplete for the 296 
following reasons; 25% of patients had no MEWS recorded, 20% had treatment time missing 297 
or invalid and 14% had missing re-admission data.  298 
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 299 
Table 1 and 2 contains the summary statistics of factors previously linked to treatment time, 300 
and those new factors with evidence suggesting a significant association with treatment 301 
time, for the entire dataset. When removing the observations with censored data (I.e 302 
patients successfully treated following one ENT review), there was little to no difference in 303 
the ratios of times or the 95% CI in table 2 (see table 6 of supplementary material) justifying 304 
use of the complete dataset. 305 
 306 
Effect of patient factors and specific interventions on treatment time 307 
Table 3 contains the adjusted treatment time ratios. The final model adjusted R2 value 308 
indicated the model accounted for approximately 68.4% of the variation within the data.  309 
 310 
There was no evidence of a statistical association between a patient’s age or MEWS and 311 
their treatment time. However, there was evidence of an association between treatment 312 
time and WHO bleeding severity grade. The evidence indicated that as WHO grade 313 
increased (i.e. bleed severity increased), treatment time also increased. Individuals with 314 
WHO grade II bleeding were likely to have a treatment time 1.3 times those with grade 1 315 
(30% longer). Those with grade III bleeding were likely to have a treatment time 2.2 times 316 
those with a grade I.  317 
 318 
There was evidence to suggest that the choice of intervention given at the first review may 319 
have been dependent on the WHO grade. Evidence showed that as WHO grade increased, 320 
so did the proportion of individuals who were packed, but as WHO grade increased the 321 
proportion of those cauterised decreased. Therefore, it was considered essential to control 322 
for WHO bleeding severity score in the final model, to assess the impact of initial treatment 323 
independent of bleeding severity.  324 
 325 
From the analysis of initial ENT individual intervention to treatment time (see table 3), it can 326 
be seen that patients who were cauterised at first ENT review had 60% reduction in 327 
treatment time compared to those who were not cauterised (Adjusted ratio 0.4, 95%CI 0.3 – 328 
0.6), but individuals who were packed had a treatment time seven times longer than those 329 
who were not packed (Adjusted Ratio 7.1, 95%CI 4.3 – 11.7). This data represents the effect 330 
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of initial treatments after controlling for bleeding severity. However, if initial treatments 331 
were not successful and another review was required, the effect of cautery diminished 332 
substantially. The plot in figure 2 is an example to demonstrate how different initial ENT-333 
instigated treatments affected treatment times for a patient who was <65 years, with a 334 
WHO grade of II and MEWS of 1. Additionally, this plot demonstrates that attempting 335 
cauterisation initially, even when unsuccessful, does not increase treatment time.  336 
 337 
Effect of intervention strategy on treatment time 338 
Analysis of different intervention strategies on treatment time were conducted via Kaplan-339 
Meier estimates, as shown in Figure 3. There was no evidence of an association between 340 
either age or MEWS with treatment times within Cox’s proportional hazard model, but 341 
strong evidence of an association between treatment time and WHO bleeding severity 342 
score. The Kaplan-Meier plots showed how treatment time was less for those with a lower 343 
grade score. Patients treated with a guideline-compliant management strategy had a 344 
shorter treatment time, indicated by the Kaplan-Meier estimates with no over-lap of the 345 
95% CIs, suggesting a statistically significant effect size. Whilst the Kaplan-Meier plot 346 
indicates that the difference was substantial, it this did not control for patient age, MEWS or 347 
WHO bleeding severity grade. This association was explored using the multi-variable Cox 348 
model, Table 4, which showed that even after controlling for age and WHO grade, the 349 
hazard ratio was 6.8 (5.7-8.8). This indicated that those managed in a guideline compliant 350 
manner were seven times more likely to be successfully treated at any time point than 351 
those who were not. In real terms this means that patients who received treatments 352 
according to national guidelines were 87% more likely to be successfully treated before 353 
those who received treatments that did not follow national guidelines (HR/(1+HR)= odds of 354 
first success - (29)). The significance of the effect of WHO bleeding severity grade on 355 
treatment time indicated that those with a lower grade had a faster treatment time than 356 
those with a higher grade. 357 
 358 
Factors influencing 30-day re-admission 359 
Eighty-eight (8.9%) patients were re-admitted to ENT within 30 days of presentation. There 360 
was no significant association between re-admission and type of intervention received 361 
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during hospital treatment. The only statistically significant predictor of re-admission to ENT 362 
was a history of epistaxis in the preceding 12 months (Table 4), which more than doubled 363 
the risk of re-admission.  364 
 365 
Discussion 366 
Summary 367 
The type of initial individual intervention provided to patients with epistaxis at first review 368 
by an ENT specialist significantly affects overall treatment time, even after controlling for 369 
disease severity and subsequent interventions. Patients who received only nasal packing as 370 
their first specialist treatment took 7.1 times longer to reach haemostasis than those who 371 
were not packed. Patients that were not cauterised at first review required 2.5 times more 372 
treatment time compared to those that were. This result holds even after controlling for 373 
bleeding severity as stratified by WHO bleeding score, the only factor found to influence 374 
treatment time. Our results suggest that attempting nasal cautery reduces treatment time if 375 
successful and doesn’t increase treatment time if not successful. Initial intervention choice 376 
does not appear to have a significant impact on 30-day ENT re-attendance. Patients who 377 
received interventions in line with national guidelines were 87% more likely to successfully 378 
achieve haemostasis before those that did not.  379 
 380 
Equally interesting are the negative results. The majority of cases of were managed by 381 
junior doctors (usually less than 18 months of ENT experience), but the grade of treating 382 
doctor did not affect the outcome in terms of treatment time or re-ttendance rate. The 383 
majority of patients had hypertension (55.4%) or were taking anti-thrombotics (57.1%), but 384 
the presence of these factors did not have an impact on treatment time or re-attendance 385 
either.  386 
 387 
Our findings in the context of the available literature 388 
A previous smaller audit of in-hospital epistaxis management across six sites demonstrated 389 
similar mean length of stay(23), but due to the limited sample size inferential analysis could 390 
not be undertaken. Whilst there have been studies that have suggested worse treatment 391 
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outcomes for patients with ischaemic heart disease (12), hypertension (11), diabetes (17) 392 
and the use of antithrombotics(17), our study shows that once admitted to hospital and the 393 
severity of epistaxis is accounted for, these factors do not seem to affect treatment 394 
outcomes. The reason for the difference may be that these studies included smaller 395 
numbers, collected data retrospectively through case notes and defined success as not 396 
representing to hospital within two weeks of treatment.  397 
 398 
Our study shows no difference in recurrence up to 30 days after hospital discharge, whether 399 
patients were cauterised or packed at first specialist review. Contradicting these findings, a 400 
retrospective audit on more than 300 adults with epistaxis attending a Canadian emergency 401 
room (30) showed reduced 14-day recurrence in patients who were cauterised compared to 402 
packed. However, nasal packing in the emergency room frequently requires re-attendance 403 
to remove the pack, and so this retrospective study may have misclassified re-attendance to 404 
remove pack with re-attendance to treat recurring epistaxis. Additionally, the case-mix of 405 
patients is unlikely to be comparable since our cohort only included those that had failed 406 
emergency room treatment, and probably represent those with more severe epistaxis.  407 
 408 
Strengths and weaknesses 409 
This is the largest prospective study of in-hospital epistaxis management to date, with 410 
sufficiently detailed information to allow assessment of interventions and management 411 
strategy after controlling for patient (age, co-morbidities), disease (severity of bleeding) and 412 
treatment factors (grade of doctor and other therapies initiated). Our statistical strategy 413 
allowed us to better understand treatment effects by focusing on initial intervention and 414 
the overall management strategy (temporal sequence of treatments initiated).  415 
However, whilst our results suggest that cauterisation at initial ENT review reduces overall 416 
treatment time, irrespective of bleeding severity, care must be taken since bleeding severity 417 
was assessed by the WHO bleeding score. WHO bleeding score provided a convenient 418 
method by which to categorise bleed severity, but in practice it might prove difficult to 419 
stratify patients’ interventions by this score alone. Unfortunately, it seems the MEWS was 420 
not sensitive enough to identify differences in the bleed severity of a patient, potentially 421 
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indicating that further work for a more tailored grading system for bleed severity is 422 
required. 423 
 424 
There were only 88 patients who re-attended to ENT for epistaxis. As mentioned earlier, we 425 
estimated differences between groups would have to be approximately 10% to be 426 
statistically significant when comparing proportion between two groups. Therefore, it is a 427 
highly probable that this data lacks the sensitivity to detect clinically important differences 428 
that are less than 10%.  429 
 430 
Implications for future research and policy 431 
Whilst these analyses suggest an increased role for nasal cautery at first specialist review, it 432 
must be noted that cautery can cause severe complications (31), and enforcing nasal 433 
cautery upon an inexperienced practitioner (87% of the patients were seen by junior 434 
doctors) may increase complication rates. On the other hand, 23% of patients that had a 435 
pack inserted in the emergency department had their pack removed for an examination 436 
when first reviewed by ENT, and only 30% of those with no packs had cautery attempted. 437 
This suggests there may be a culture or system in place that encourages rapid arrest of the 438 
epistaxis with nasal packing rather than deliberated nasal examination to assess for bleeding 439 
point. This may relate to the availability of expertise and or equipment. Further studies 440 
would help investigate the issues surrounding the reasons for the choice of intervention in 441 
more detail.  442 
 443 
Whilst INTEGRATE and the BRS developed national guidelines to help align treatment 444 
pathways with best available evidence, these guidelines were not widely publicised prior to 445 
the national audit. However, they were drawn up to reflect a logical sequence of 446 
interventions based on widely available evidence, and so it is surprising that only 30% of 447 
patients received treatments that followed an evidence-based course. Whilst treatment 448 
pathways should be adapted to the resource availability of local departments, there is clear 449 
evidence from our analyses that following national guidance can reduce treatment time 450 
without compromising 30-day re-attendance, and local departments should be encouraged 451 
to adapt their resources to better comply with these guidelines.  452 
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 453 
Trainees collaborated nationally to deliver the largest study of inpatient epistaxis 454 
management to date, designing and leading research into a condition that has a large 455 
disease burden. Undertaking this study has not only highlighted new evidence relating to 456 
epistaxis, but it has encouraged the new generation of surgeons to better appreciate 457 
research as a common tool to resolve critical clinical problems.  458 
 459 
 460 
 461 
  462 
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Tables and Figures 563 
 564 
 565 
Figure 1 Data analysis flow chart This figure shows how data was entered onto a central database and the results of 566 
subsequent data cleaning led to different sample sizes for 3 different analyses. Patient data were initially excluded if it did 567 
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not meet inclusion criteria, or was duplicated (424 entries excluded). Further data were excluded due to missingness in 568 
variables that were considered essential for each of the three analyses.  569 
 570 
 571 
Figure 2: Expected treatment time with 95% confidence intervals of patients by cauterisation status: successful (dark green 572 
square and light green bars); failed (red circle with orange dashed bars); not cauterised (blue triangle with light blue dotted 573 
bars) and packing status (not packed or packed) at first ENT review. This graphic demonstrates that cauterising reduces 574 
treatment time if successful but does not change treatment time if unsuccessful.  Additionally, those who are packed have 575 
the longest treatment times of all treatment arms.  576 
 577 
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 578 
Figure 3: Kaplan-Meier estimates and 95% confidence intervals of treatment time by intervention strategy: guideline 579 
compliant (dark green line and 95% CI shaded in light green) and non-compliant (blue dashed line with 95% CI shaded in 580 
light blue). This graph shows that when treatment follows national guidance treatment time reduces significantly.  581 
 582 
 583 
 
N (%) 
Treatment Time in hrs 
Mean (95% CI)1 [Range] Total 
No 
Re-
Admission 
896 (91.1) 
30-day 
Re-
Admission 
88 (8.9) 
Age Group in years:      
 < 65 325 (29.0) 261 (90.0) 29 (10.0) 7.0 (5.6, 8.9) [0.0 – 152.3] 
 65 ≤ Age < 75 278 (24.8) 223 (91.0) 29 (9.0) 6.2 (4.9, 7.9) [0.0 – 114.9] 
 75 ≤ Age < 85 313 (28.0) 248 (92.5) 20 (7.5) 9.0 (7.2, 11.1) [0.0 – 109.0] 
 ≥ 85 203 (18.1) 162 (90.5) 17 (9,5) 5.5 (4.2, 17.8) [0.1 – 144.6] 
Gender:      
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 Female 492 (43.9) 394 (91.0) 39 (9.0) 6.2 (5.1, 7.4) [0.0 – 144.6] 
 Male 630 (56.1) 502 (91.1) 49 (8.9) 7.6 (6.5, 8.9) [0.0 – 152.3] 
WHO     
 Grade I 143 (12.8) 96 (90.6) 10 (9.4) 2.0 (1.4, 2.9) [0 – 104.0] 
 Grade II 922 (82.7) 758 (91.7) 69 (7.8) 7.8 (6.8, 8.8) [0.0 – 143.2] 
 Grade III 50 (4.5) 36 (81.8) 8 (18.2) 
28.7 (19.3, 44.9) [0.2 – 
152.3] 
MEWS     
 0 232 (27.6) 196 (90.7) 20 (9.3) 7.0 (5.4, 9.1) [0.0 – 118.4] 
 1 307 (36.5) 248 (90.7) 21 (7.8) 7.2 (5.7, 9.1) [0.0 – 116.4] 
 2 150 (17.8) 113 (89.0) 14 (11.0) 8.3 (6.2, 11.3) [0.2 – 152.3] 
 3 93 (11.1) 75  (88.2) 10 (11.8) 10.0 (6.9, 14.6) [0.1 – 104.0] 
 ≥ 4 59 (7.0) 55 (100.0) 0 (0.0) 14.0 (9.4, 21.0) [0.3 – 109.0] 
Diabetes     
 No 930 (85.6) 751 (92.3) 63 (7.7) 6.9 (6.0, 7.9) [0.0 – 143.2] 
 Yes 156 (14.4) 119 (85.0) 21 (15.0) 8.9 (6.5, 12.1) [0.0 – 152.3] 
Hypertension     
 No 498 (44.6) 369 (91.0) 39 (9.0) 5.5 (4.6, 6.7) [0.0 – 143.2] 
 Yes 618 (55.4) 495 (91.0) 49 (9.0) 8.3 (7.1, 9.7) [0.0 – 152.3] 
Heart Disease     
 No 762 (69.6) 611 (91.6) 56 (8.4) 6.6 (5.7, 7.6) [0.0 – 143.2] 
 Yes 333 (30.4) 267 (90.5) 28 (9.5) 8.8 (7.1, 10.9) [0.0-152.3] 
Previous Epistaxis     
 No 808 (74.0) 661 (93.1) 49 (6.9) 6.5 (5.6, 7.5) [0.0 – 130.6]] 
 Yes 284 (26.0) 207 (84.1) 39 (15.9) 8.5 (5.7, 10.7) [0.0 – 152.3] 
Antithrombotic     
 No 475 (42.9) 367 (89.5) 43 (10.5) 6.0 (5.0, 7.3) [0.0 – 143.2] 
 Yes 631 (57.1) 514 (91.9) 45 (8.1) 7.9 (6.7, 9.2) [0.0 – 152.3] 
Table 1: Summary statistics of 30-day readmission and treatment time by patient’s medical history. This is extracted from 584 
the raw dataset. Analysis was done on a subset who had sufficient data regarding outcomes for analysis and therefore final 585 
analysis is only on 834 patients.  1 Geometric mean and 95% CI 586 
 587 
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 588 
 589 
 
N (%) 
Treatment Time in hrs 
Mean (95% CI)1 [Range] Total 
No 
Re-
Admission 
896 (91.1) 
30-day 
Re-
Admission 
88 (8.9) 
Packed at ED     
 No 605 (53.9) 469 (90.7) 48 (9.3) 3.4 (2.8, 4.0) [0.0 – 144.6] 
 Yes 517 (46.1) 427 (91.4) 40 (8.6) 
16.2 (14.2, 18.4) [0.0 – 
152.3] 
Cauterised at 1st ENT 
review 
   
 
 No 757 (67.5) 600 (90.9) 60 (9.1) 
17.1 (15.4, 18.9) [0.0 – 
152.3] 
 Yes 365 (32.5) 296 (91.4) 28 (8.6) 1.1 (0.9, 1.3) [0.0 – 116.4]  
Packed at 1st ENT     
 No2 443 (39.5) 345 (90.6) 551 (9.4) 1.1 (0.9, 1.3) [0.0 – 104.0] 
 Yes 679 (60.5) 551(91.4) 52 (8.6) 
23.0 (21.2, 24.9) [0.0 – 
152.3] 
Dr Grade at 1st ENT     
 Nurse 38 (3.5) 34 (91.9) 3 (8.1) 2.3 (1.2, 4.5) [0.2 – 63.7] 
 Junior 950 (86.6) 751 (91.4) 71 (8.6) 7.3 (6.5, 8.4) [0.0 – 152.3] 
 Middle 101 (9.2) 84 (87.5) 12 (12.5) 8.5 (5.8, 12.5) [0.0 – 109.0] 
 Consultant 8 (0.7) 6 (85.7) 1 (14.3) 3.2 (0.7, 14.1) [0.3 – 42.8] 
Interventions after 
1st ENT 
   
 
 No 365 (62.5) 288 (91.7) 26 (8.3) 0.7 (0.6, 0.8) [0.0 – 26.0] 
 Yes 757 (67.5) 608 (90.7) 62 (9.3) 
21.2 (19.5, 23.0) [0.0 – 
152.3] 
Surgery     
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 No 
1080 
(96.9) 
866 (91.4) 81 (8.6) 
6.5 (5.8, 7.4) [0.0 – 152.3] 
 Yes 35 (3.1) 24 (80.0) 6 (20.0) 
42.1 (32.9, 54.0) [8.8 – 
144.6] 
Intervention 
Strategy 
   
 
 Compliant 334 (29.8) 626 (91.0) 62 (9.0) 0.7 (0.6, 0.9) [0.0 – 50.5] 
 Non-
compliant 
788 (70.2) 270 (91.2) 26 (8.8) 
18.1 (16.4, 19.9) [0.0 – 
152.3] 
1 Geometric mean and 95% CI 590 
2 Includes those whose ED pack was removed 591 
Table 2: Summary statistics of 30-day re-admission and treatment time by patient’s Epistaxis management.  592 
 593 
 594 
 595 
Factor  Adjusted Ratio (95% CI) 2 p-value 
Packed at first ENT review No 1 - 
 
Yes 7.1 (4.3 – 11.7) < 0.001 
Cauterised at first ENT 
review No 1  - 
 
Yes 0.4 (0.3 – 0.6) < 0.001 
1 Summary statistics for patients with complete model data 596 
2 Adjusted for severity scores (MEWS and WHO), age and subsequent treatment after the initial ENT review. 597 
Table 3: Initial ENT treatments and their effect on overall treatment time. Table of the number (N) and percentage of total 598 
within each variable category; the median and Interquartile range of treatment time in hours; and the ratio and 95% 599 
confidence intervals. 600 
 601 
Factor  Adjusted Hazard Ratio 
(95% CI) 
p-value 
Guideline compliant No 1 - 
 Yes 6.8 (5.7, 8.2) < 0.001 
Age Group < 65 1 - 
 65 ≤ Age < 75 1.1 (0.9, 1.3) 0.3 
 75 ≤ Age < 85 0.9 (0.7, 1.0) 0.1 
 ≥ 85 1.2 (1.0, 1.5) 0.04 
MEWS 0 1 - 
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 1 0.9 (0.7, 1.1) 0.2 
 2 1.0 (0.8, 1.2) 0.8 
 3 0.9 (0.7, 1.2) 0.6 
 ≥ 4 1.0 (1.0, 1.5) 0.8 
WHO Grade I 1 - 
 II 0.8 (0.6, 1.0) 0.02 
 III 0.3 (0.2, 0.5) < 0.001 
 1 Summary statistics are for patients with complete model data 602 
2 Adjusted for severity scores (MEWS and WHO) and age. 603 
Table 4: Adjusted Cox’s proportional hazards model of time to achieve haemostasis by intervention strategy. 604 
Factor  Adjusted Odds Ratio (95% CI)1 p-value 
History of Epistaxis No 1 - 
 Yes 2.4 (1.4 – 3.9) 0.001 
1 Adjusted for severity scores (MEWS and WHO) and age. 605 
Table 5: Role of Initial ENT treatment and admission patient and disease characteristics on 30-day epistaxis related ENT re-606 
admission.  607 
 608 
Supplementary material 609 
 610 
  Adjusted Ratio (95% CI)  p-value 
Sensitivity Analysis 1    
Packed at first ENT review No 1 - 
 
Yes 7.0 (4.3 - 11.8) < 0.001 
Cauterised at first ENT 
review No 1 - 
 
Yes 0.4 (0.3 – 0.6) < 0.001 
Sensitivity Analysis 2    
Packed at first ENT review No 1 - 
 Yes 7.5 (4.5 – 12.5) < 0.001 
Cauterised at first ENT 
review No 
1 
- 
 Yes 0.5 (0.3 – 0.7) < 0.001 
Sensitivity Analysis 3    
Packed at first ENT review No 1 - 
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 Yes 2.3 (1.8 – 3.0) < 0.001 
Cauterised at first ENT 
review No 
1 
- 
 Yes 0.9 (0.7 – 1.2) 0.59 
Table 6: Sensitivity Analysis 1: log linear regression model removing censored observations. Sensitivity Analysis 1: log linear 611 
regression model of patients who did not require further interventions after their initial ENT intervention. Sensitivity 612 
Analysis 1: log linear regression model of observations who required further interventions after their initial ENT 613 
intervention. 614 
 615 
 616 
Figure 4: Kaplan-Meier estimates and 95% confidence intervals of treatment time by WHO bleeding grade: WHO I (blue 617 
dashed line with 95% CI shaded in light blue); WHO II (dark green line and 95% CI shaded in light green); WHO III (dark red 618 
dotted line and 95% CI shaded in red).. 619 
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 620 
Figure 5 Derived epistaxis management steps based on BRS guidelines. The above flow chart shows the potential steps in 621 
managing a patient with epistaxis. These steps were adapted from BS epistaxis management guidance and each steps 622 
describes the subsequent treatment if previous has failed.  623 
 624 
  625 
Definitive treatment
Surgical or radiological depending on centre availability
Temporising measure to definitive treatmetn
If unable to stop bleeding, stabilise use temporising measures (e.g. nasal pack, fluids, tranxexamic acid, haemostatic agents) and 
proceed to definitive treatment
Review patient <24 hours
Remove nasal packing and re-attempt above steps
Nasal tamponade packing
If above fails or unable to find source with torrential bleeding, insert non-dissolvable nasal packing 
Cauterise and consider adjuncts
Nasal cautery with topical silver nitrate or electrocautery if available. Consider tranexamic acid, and haemostatic agents if available
Nasal Examination
Thorough nasal examination, remove pack if pre-inserted, endoscope if available, identify source of bleeding (may require suction 
and temporaray haemostasis with topical vasoconstricors) 
Stabilise
Airways, Breathing, Circulation Approach, with treatment of shock as necessary, epistaxis can be managed by conservative measures 
such as alar pinch and ice
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